Mr. Le Xiao, a senior financial expert, joined MegaRobo technology as CFO
On July 22, 2022, MegaRobo announced that Mr. Le Xiao, a senior financial expert, formally joined the company as CFO to be fully responsible for MegaRobo's corporate financial management, international business development, investment and acquisition, investor relations, etc., helping to achieve the company's strategic objectives and laying a solid foundation for the company's long-term sustainable development.
Mr. Huang Yuqing, founder and CEO of MegaRobo, said: "We are very happy that Mr. Le Xiao can join the company in the critical period of the rapid development of MegaRobo. We believe that his professional financial background, rich experience, and international vision will help the company to upgrade to a new level in financial strategic planning, capital operation, and other fields, accelerate the internationalization process, and promote the realization of the vision and mission of 'creating a more efficient, healthier and better world for everyone."
Mr. Le Xiao said: "MegaRobo is an innovative driver of intelligent automation in the fields of life sciences and semiconductors in recent years. It is a great honor to join MegaRobo and personally participate in promoting and witnessing the breakthroughs and development of automation and intellectualization in the fields of life sciences. In the future, scientific research will be led by automation and intellectualization, generate more scientific innovations more efficiently, and create a better working and living environment for everyone. We are very excited to be able to participate in this process To contribute to the birth and industrialization of cutting-edge science. I will try my best to accomplish every small goal. "
Mr. Le Xiao is a senior expert in finance and medical investment. He has profound professional background and rich project experience in capital operation, investment and financing, and M & A transactions. He also has cross-cultural work management experience in North America, Asia, and other places. Before joining MegaRobo, Mr. Le Xiao worked in the strategic investment department of WuXi AppTec, a leading enterprise in China's CRO / CDMO industry. He led many strategic investments in the fields of life science, innovative treatment, and innovative payment. He played an important role in WuXi AppTec's acquisition of the Swiss production base of Bristol Myers Squibb. He also discovered and led the b-round financing of MegaRobo technology in the early stage. On behalf of WuXi AppTec, Mr. Le Xiao also served as a director of its joint-stock companies, Canbridge and Ambrx Biopharma, helping them to be listed on the Hong Kong stock exchange of China and the New York Stock Exchange of the United States.
Before this, Mr. Le Xiao worked as venture capital in 6 Dimensions Capital, a leading investment institution focusing on the field of life science and medical health. He also worked in Integral Derivatives, the largest stock options market maker on Wall Street, and Bank of America Merrill Lynch. He also worked in Fapon, a leading in vitro diagnostic platform enterprise in the industry. Mr. Le Xiao has a master's degree from the Massachusetts Institute of Technology and a bachelor's degree from Johns Hopkins University.
MegaRobo completed round C financing in June this year. This round of raised funds is used to deepen R & D investment and capacity expansion in the field of life science intelligent automation, and actively expand the business and accelerate the internationalization process. The existing major shareholders of the company are top strategic and financial investment institutions.